Magnesium side effects: what 81,658 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Detox Toc Toc
Who reports
81,658 reports · 62% serious · 6,009 with death outcome · 70% female
Used for
place enough product on hadns to cover all surfaces. rub hands together until dry. supervise children uner 6 years of age when using this product to avoid swallowing.
What it is
Magnesium atom is an alkaline earth metal atom. It has a role as a macronutrient.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,141 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Grip strength | 119 | 272.8 210.6–353.5ROR 273.2 · calibrated p 5e-11 ✓ | 128.9 EB05 110.6 · IC025 +6.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=119 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Vaginal flatulence | 102 | 128.6 101.3–163.2ROR 128.8 · calibrated p 2e-8 ✓ | 84.2 EB05 71.4 · IC025 +5.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=102 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Swollen joint count | 74 | 110.4 84.0–145.1ROR 110.5 · calibrated p 9e-8 ✓ | 75.7 EB05 62.3 · IC025 +5.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=74 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Lupus vulgaris | 349 | 106.6 94.0–120.7ROR 107.0 · calibrated p 7e-8 ✓ | 74.9 EB05 68.5 · IC025 +5.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=349 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Deep vein thrombosis postoperative | 550 | 100.1 90.7–110.4ROR 100.8 · calibrated p 1e-7 ✓ | 71.8 EB05 66.9 · IC025 +5.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=550 · ♀ 100% (drug 70%) · 92% clinician | no trial arm names this drug |
| C-reactive protein | 253 | 99.2 85.8–114.8ROR 99.5 · calibrated p 1e-7 ✓ | 71.1 EB05 64.1 · IC025 +5.8 3/3 methods agree | Lab value / disease marker | serious n=253 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 130 | 62.0 51.2–75.1ROR 62.1 · calibrated p 4e-6 ✓ | 49.6 EB05 42.9 · IC025 +5.1 3/3 methods agree | Lab value / disease marker | serious n=130 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Swollen joint count increased | 604 | 61.5 56.3–67.3ROR 62.0 · calibrated p 3e-6 ✓ | 49.6 EB05 46.4 · IC025 +5.4 3/3 methods agree | Lab value / disease marker | serious n=604 · ♀ 100% (drug 70%) · 94% clinician | no trial arm names this drug |
| Rheumatic fever | 766 | 54.5 50.4–58.9ROR 55.0 · calibrated p 8e-6 ✓ | 44.9 EB05 42.3 · IC025 +5.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=765 · ♀ 100% (drug 70%) · 94% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 350 | 53.8 48.0–60.4ROR 54.1 · calibrated p 9e-6 ✓ | 44.4 EB05 40.7 · IC025 +5.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=346 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| X-ray abnormal | 303 | 52.4 46.3–59.3ROR 52.6 · calibrated p 1e-5 ✓ | 43.4 EB05 39.5 · IC025 +5.2 3/3 methods agree | Lab value / disease marker | serious n=303 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Facet joint syndrome | 472 | 45.1 40.9–49.7ROR 45.3 · calibrated p 3e-5 ✓ | 38.3 EB05 35.5 · IC025 +5.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=472 · ♀ 100% (drug 70%) · 92% clinician | no trial arm names this drug |
| Dislocation of vertebra | 332 | 44.9 40.0–50.5ROR 45.1 · calibrated p 3e-5 ✓ | 38.2 EB05 34.9 · IC025 +5.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=332 · ♀ 100% (drug 70%) · 90% clinician | no trial arm names this drug |
| Peripheral venous disease | 548 | 40.7 37.2–44.6ROR 41.0 · calibrated p 5e-5 ✓ | 35.2 EB05 32.8 · IC025 +5.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=542 · ♀ 100% (drug 70%) · 91% clinician | no trial arm names this drug |
| Retinitis | 201 | 35.0 30.2–40.6ROR 35.1 · calibrated p 1e-4 ✓ | 30.8 EB05 27.4 · IC025 +4.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=201 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 826 | 33.7 31.3–36.2ROR 34.0 · calibrated p 1e-4 ✓ | 29.8 EB05 28.1 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious PRR 27.7 · ♀ 100% (drug 70%) · 94% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 851 | 33.6 31.3–36.0ROR 33.9 · calibrated p 1e-4 ✓ | 29.7 EB05 28.1 · IC025 +4.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 27.5 · ♀ 100% (drug 70%) · 94% clinician | no trial arm names this drug |
| Porphyria acute | 160 | 33.5 28.4–39.6ROR 33.6 · calibrated p 2e-4 ✓ | 29.6 EB05 26.0 · IC025 +4.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=158 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 647 | 32.3 29.8–35.1ROR 32.6 · calibrated p 2e-4 ✓ | 28.7 EB05 26.9 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=646 · ♀ 100% (drug 70%) · 95% clinician | no trial arm names this drug |
| C-reactive protein abnormal | 627 | 27.8 25.6–30.1ROR 28.0 · calibrated p 4e-4 ✓ | 25.1 EB05 23.5 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious n=627 · ♀ 100% (drug 70%) · 95% clinician | no trial arm names this drug |
| Muscle injury | 752 | 25.8 23.9–27.8ROR 26.0 · calibrated p 6e-4 ✓ | 23.5 EB05 22.1 · IC025 +4.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 23.4 · ♀ 100% (drug 70%) · 93% clinician | no trial arm names this drug |
| Folliculitis | 812 | 21.8 20.3–23.4ROR 22.0 · calibrated p 0.001 ✓ | 20.2 EB05 19.0 · IC025 +4.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 21.7 · ♀ 100% (drug 70%) · 92% clinician | no trial arm names this drug |
| Helicobacter infection | 800 | 21.8 20.3–23.4ROR 22.0 · calibrated p 0.001 ✓ | 20.1 EB05 19.0 · IC025 +4.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 19.5 · ♀ 100% (drug 70%) · 92% clinician | no trial arm names this drug |
| Breast cancer stage iii | 502 | 21.6 19.8–23.7ROR 21.8 · calibrated p 0.001 ✓ | 20.0 EB05 18.6 · IC025 +4.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=502 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Pemphigus | 957 | 21.3 20.0–22.8ROR 21.6 · calibrated p 0.001 ✓ | 19.7 EB05 18.7 · IC025 +4.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 18.3 · ♀ 100% (drug 70%) · 96% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 493 | 21.2 19.4–23.2ROR 21.3 · calibrated p 0.001 ✓ | 19.6 EB05 18.2 · IC025 +4.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=487 · ♀ 100% (drug 70%) · 92% clinician | no trial arm names this drug |
| Drug tolerance decreased | 193 | 18.9 16.4–21.9ROR 19.0 · calibrated p 0.003 ✓ | 17.7 EB05 15.7 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=177 · ♀ 100% (drug 70%) | no trial arm names this drug |
| Bone erosion | 240 | 18.6 16.3–21.2ROR 18.6 · calibrated p 0.003 ✓ | 17.4 EB05 15.6 · IC025 +3.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=240 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Lip dry | 601 | 18.4 16.9–20.0ROR 18.5 · calibrated p 0.003 ✓ | 17.2 EB05 16.1 · IC025 +4.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=588 · ♀ 100% (drug 70%) · 91% clinician | no trial arm names this drug |
| Infusion site reaction | 193 | 18.2 15.7–21.0ROR 18.2 · calibrated p 0.003 ✓ | 17.0 EB05 15.1 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=166 · ♀ 100% (drug 70%) | no trial arm names this drug |
| Female genital tract fistula | 112 | 17.8 14.7–21.6ROR 17.8 · calibrated p 0.004 ✓ | 16.6 EB05 14.2 · IC025 +3.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=112 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Blood magnesium decreased | 540 | 17.1 15.6–18.6ROR 17.2 · calibrated p 0.004 ✓ | 16.0 EB05 14.9 · IC025 +3.8 3/3 methods agree | Lab value / disease marker | serious PRR 15.0 | no trial arm names this drug |
| Autoimmune disorder | 597 | 17.0 15.7–18.5ROR 17.1 · calibrated p 0.004 ✓ | 16.0 EB05 14.9 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 15.6 · ♀ 100% (drug 70%) | no trial arm names this drug |
| Seronegative arthritis | 70 | 17.0 13.4–21.7ROR 17.0 · calibrated p 0.005 ✓ | 15.9 EB05 13.0 · IC025 +3.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=70 · ♀ 100% (drug 70%) · 100% clinician | no trial arm names this drug |
| Hand deformity | 795 | 16.5 15.4–17.8ROR 16.7 · calibrated p 0.004 ✓ | 15.6 EB05 14.7 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 15.6 · ♀ 100% (drug 70%) · 93% clinician | no trial arm names this drug |
| Blepharospasm | 377 | 16.5 14.9–18.4ROR 16.6 · calibrated p 0.005 ✓ | 15.6 EB05 14.3 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=355 · ♀ 100% (drug 70%) | no trial arm names this drug |
| Wound infection | 642 | 16.1 14.8–17.4ROR 16.2 · calibrated p 0.005 ✓ | 15.1 EB05 14.2 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 15.0 · ♀ 97% (drug 70%) | no trial arm names this drug |
| Bursitis | 705 | 15.9 14.7–17.1ROR 16.0 · calibrated p 0.005 ✓ | 15.0 EB05 14.1 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 15.9 · ♀ 97% (drug 70%) | no trial arm names this drug |
| Live birth | 479 | 15.6 14.2–17.1ROR 15.7 · calibrated p 0.006 ✓ | 14.7 EB05 13.7 · IC025 +3.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 16.6 · ♀ 100% (drug 70%) · 93% clinician | no trial arm names this drug |
| Pericarditis | 951 | 15.5 14.5–16.5ROR 15.6 · calibrated p 0.006 ✓ | 14.6 EB05 13.9 · IC025 +3.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 13.6 · ♀ 100% (drug 70%) · 94% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Tendon disorder | 642 | 4.44.1–4.7 | signal |
| Depression | 2,641 | 2.42.3–2.5 | signal |
| Arrhythmia / qt | 1,760 | 2.32.2–2.5 | signal |
| Fall / fracture | 3,440 | 2.32.3–2.4 | signal |
| Serious infection | 6,852 | 2.32.2–2.3 | signal |
| Anaemia | 2,627 | 2.32.2–2.3 | signal |
| Interstitial lung disease | 812 | 2.22.0–2.3 | signal |
| Liver injury | 2,230 | 1.91.8–2.0 | raised |
| Thrombocytopenia | 1,531 | 1.81.7–1.9 | raised |
| Hyponatraemia | 559 | 1.81.6–1.9 | raised |
| Hyperglycaemia / diabetes | 2,331 | 1.71.7–1.8 | raised |
| Opportunistic infection | 911 | 1.71.6–1.8 | raised |
| Gi bleeding | 1,192 | 1.71.6–1.8 | raised |
| Pancreatitis | 521 | 1.71.5–1.8 | raised |
| Venous thromboembolism | 1,240 | 1.51.4–1.6 | raised |
| Kidney injury | 2,530 | 1.41.4–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Fatigue (tiredness) | 8,939 | 3.0 2.9–3.0ROR 3.2 · calibrated p 0.559 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.7 · serious PRR 3.4 | no trial arm names this drug |
| Nausea | 7,017 | 2.3 2.2–2.3ROR 2.4 · calibrated p 0.850 | 2.3 EB05 2.2 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.2 · serious PRR 2.8 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 6,848 | 2.8 2.7–2.8ROR 2.9 · calibrated p 0.656 | 2.7 EB05 2.7 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.4 · serious PRR 3.0 | no trial arm names this drug |
| Headache | 6,175 | 2.5 2.5–2.6ROR 2.7 · calibrated p 0.743 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.5 · serious PRR 3.1 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 5,814 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.402 | 1.1 EB05 1.1 · IC025 +0.1 | Reporting / coding artifact | age-adj. PRR 1.5 · serious PRR 1.8 | no trial arm names this drug |
| Pain | 5,528 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.851 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.7 · serious PRR 2.5 | no trial arm names this drug |
| Off label use (used outside approved label) | 5,239 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.700 | 1.5 EB05 1.5 · IC025 +0.6 | Reporting / coding artifact | age-adj. PRR 1.5 · serious PRR 1.9 | no trial arm names this drug |
| Dizziness | 5,162 | 2.7 2.6–2.8ROR 2.8 · calibrated p 0.698 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.5 · serious PRR 3.0 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 5,098 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.851 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.1 · serious PRR 2.4 | no trial arm names this drug |
| Arthralgia (joint pain) | 4,808 | 3.0 2.9–3.1ROR 3.1 · calibrated p 0.587 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 3.0 · serious PRR 3.8 | no trial arm names this drug |
| Asthenia (weakness) | 4,419 | 3.0 3.0–3.1ROR 3.2 · calibrated p 0.578 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.6 · serious PRR 3.1 | no trial arm names this drug |
| Vomiting | 3,876 | 2.1 2.1–2.2ROR 2.2 · calibrated p 0.958 | 2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.1 · serious PRR 2.4 | no trial arm names this drug |
| Malaise (feeling unwell) | 3,464 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.985 | 2.0 EB05 2.0 · IC025 +1.0 | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.0 · serious PRR 2.4 | no trial arm names this drug |
| Pain in extremity | 3,407 | 3.0 2.9–3.1ROR 3.1 · calibrated p 0.604 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.8 · serious PRR 3.6 | no trial arm names this drug |
| Rash | 3,321 | 2.0 1.9–2.0ROR 2.0 · calibrated p 0.952 | 2.0 EB05 1.9 · IC025 +0.9 | No label text to screen label has no adverse-reaction text | age-adj. PRR 2.1 · serious PRR 2.8 | no trial arm names this drug |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Magnesium?
In FDA FAERS, the most frequently co-reported reaction terms for Magnesium are fatigue, nausea, diarrhoea, headache, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Magnesium have an FDA boxed warning?
No. The FDA label retrieved for Magnesium has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Magnesium causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 47ec6277-e411-af82-e063-6294a90ac8c1, effective 20260108; matched on
openfda.generic_name.exact:"MAGNESIUM") - PubChem CID 5462224 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,181 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
MAGNESIUM, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.